Thompson Investment Management Inc. Purchases 499 Shares of Abbott Laboratories (NYSE:ABT)

Thompson Investment Management Inc. boosted its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,672 shares of the healthcare product maker’s stock after purchasing an additional 499 shares during the period. Thompson Investment Management Inc.’s holdings in Abbott Laboratories were worth $1,054,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Scissortail Wealth Management LLC acquired a new position in Abbott Laboratories during the first quarter valued at approximately $1,475,747,000. Aspire Private Capital LLC acquired a new stake in shares of Abbott Laboratories in the first quarter valued at approximately $16,271,874,000. Graham Capital Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the first quarter valued at approximately $244,037,000. Altshuler Shaham Ltd acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $28,000. Finally, Financial Gravity Asset Management Inc. lifted its position in shares of Abbott Laboratories by 134.5% in the first quarter. Financial Gravity Asset Management Inc. now owns 258 shares of the healthcare product maker’s stock valued at $316,000 after buying an additional 148 shares during the last quarter. 73.70% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 10,400 shares of Abbott Laboratories stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $105.03, for a total transaction of $1,092,312.00. Following the transaction, the executive vice president now directly owns 65,027 shares of the company’s stock, valued at approximately $6,829,785.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Daniel J. Starks sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $113.76, for a total transaction of $5,688,000.00. Following the transaction, the director now directly owns 6,775,316 shares of the company’s stock, valued at approximately $770,759,948.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 10,400 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $105.03, for a total value of $1,092,312.00. Following the transaction, the executive vice president now directly owns 65,027 shares in the company, valued at $6,829,785.81. The disclosure for this sale can be found here. Company insiders own 1.10% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock traded down $0.91 during midday trading on Friday, reaching $101.74. 8,303,319 shares of the stock were exchanged, compared to its average volume of 4,914,443. The stock has a market capitalization of $176.56 billion, a PE ratio of 34.73, a P/E/G ratio of 4.59 and a beta of 0.68. Abbott Laboratories has a 52 week low of $93.25 and a 52 week high of $115.83. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.64 and a quick ratio of 1.16. The company has a fifty day moving average price of $106.26 and a 200 day moving average price of $105.17.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 20th. The healthcare product maker reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. The business had revenue of $9.98 billion for the quarter, compared to analyst estimates of $9.71 billion. Abbott Laboratories had a return on equity of 20.50% and a net margin of 12.83%. Abbott Laboratories’s quarterly revenue was down 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.43 EPS. As a group, analysts expect that Abbott Laboratories will post 4.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. StockNews.com assumed coverage on Abbott Laboratories in a research report on Thursday, August 17th. They issued a “buy” rating for the company. Mizuho lifted their price target on Abbott Laboratories from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Wolfe Research raised Abbott Laboratories from an “underperform” rating to a “peer perform” rating in a report on Friday, July 21st. Morgan Stanley reissued an “equal weight” rating and set a $112.00 price target on shares of Abbott Laboratories in a report on Friday, July 21st. Finally, Barclays lifted their price target on Abbott Laboratories from $127.00 to $132.00 and gave the stock an “overweight” rating in a report on Monday, July 24th. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $120.82.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.